Treatment with the second-generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1.

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.

Advertisements

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.

Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Jacobson IM, et al.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study Phase 3 Treatment-Naïve and Treatment-Experienced Nelson DR,

SMV + PEG-IFN + RBV Open-label W12 W24* or W48* N = years Chronic HCV infection Genotype 4 Treatment-naïve or experienced with relapse or partial.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Genotype 1 NIAID/NIH Trial Phase 2, Treatment Naïve Treatment Naïve (unfavorable.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial Phase 3 Treatment Naïve and Treatment Experienced.

Asselah T. AASLD 2015, Abs OSIRIS  Design SMV + PEG-IFN + RBV Open label Chronic HCV infection Genotype 4 Treatment-naïve Mild to moderate fibrosis.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.

Hepatitis web study Hepatitis web study Elbasvir-Grazoprevir in Treatment-Naïve HCV Genotype 1, 4 or 6 C-EDGE Treatment Naïve (TN) Phase 3 Treatment Naïve.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.

SOF + RBV GT2 Japanese SOF + RBV Open-label Japanese SOF + RBV Study: SOF + RBV in genotype 2  Design W12 Japanese patients ≥ 20 years Chronic HCV infection.

No cirrhosis or compensated cirrhosis * No HBV or HIV coinfection

Design Randomisation* 1 : 1 Open-label W8 W12

Phase 3 Treatment-Naïve and Treatment-Experienced

ARV-trial.com RUBY-II Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for HCV genotype 1a or 4 with severe renal impairment Design Open label W12.

Phase 3 Treatment Experienced

Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3

Design Single arm Open label W12 ≥ 18 years, HCV genotype 1 to 6

C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis

Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study

> 18 years Chronic HCV infection Compensated cirrhosis **

GARNET Study: OBV/PTV/r + DSV 8 weeks in genotype 1b

Phase 3b Treatment-Naive

Phase 3 Treatment Experienced

Failure to achieve SVR on No HBV or HIV co-infection

Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

C-BREEZE-2 Study: ruzasvir + uprifosbuvir for 12 weeks in genotype 1-6

Phase 2b Treatment-Naïve

SOF/VEL + GS-9857 in genotypes 1-6 Phase II

DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1

Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.

World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.

HCV Care in Unique Patient Populations

Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE

Simeprevir in HIV Coinfection, GT-1 C212 Trial

Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.

Phase 3 Treatment-Naïve and Treatment-Experienced

Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I

HCV Protease Inhibitors in Clinical Practice

ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.

GS-US Study: SOF/VEL + GS-9857 in genotype 1 - Phase II

Analysis of Sustained Viral Response and Boceprevir Resistance Following Combination Treatment With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in.

Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study

Volume 59, Issue 4, Pages (October 2013)

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

GS-US Study: SOF/VEL + GS in genotype 2, 3, 4 or 6 - Phase II

LEPTON Study: SOF/VEL + GS-9857 genotype 1 or 3 Phase II

Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3

Phase 2b Treatment Naïve and Treatment Experienced

Efficacy and Safety of Elbasvir/Grazoprevir in Treatment-Naïve patients with Chronic HCV GT 1, GT 4 and GT 6 Infection (C-CORAL): A Phase III Randomized.

From non-A, non-B hepatitis to hepatitis C virus cure

Daclatasvir + Asunaprevir in Genotype 1b HALLMARK-DUAL Study

HCV Protease Inhibitors in Clinical Practice

No HBV or HIV co-infection

Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.

What Does the Future Hold and What Will It Mean for Patients?

Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)

Telaprevir in Treatment Experienced GT-1 PROVE3

Phase 3 Treatment-Naïve and Treatment-Experienced

ENDURANCE-4 Study: glecaprevir/pibrentasvir in genotype 4, 5 or 6

Sequencing cohorts Open-label Design W8 W12 ≥ 18 years

Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2

Presentation transcript:

Treatment with the second-generation HCV protease inhibitor BI 201335 results in high and consistent SVR rates: Results from SILEN-C1 in HCV genotype-1 treatment-naïve patients across different baseline factors

Disclosures

Introduction

SILEN-C1 trial

Virologic responsea

Methods

Baseline characteristics

Virologic response by age and gender

Virologic response by baseline ALT and GGT

Virologic response by baseline HCV RNA

Virologic response by HCV GT-1 subtype

Virologic response by IL28B

Baseline predictors of SVR

Baseline predictors of SVR

Discussion

Acknowledgements